Speech-Language Pathologists in Spruce Pine, NC Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Ms. Bo Kyung Edwards, M.S./CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 167 Locust St, Spruce Pine, NC 28777 Phone: 828-329-6010 |
 Edwards Therapy Services Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 167 Locust Ave, Spruce Pine, NC 28777 Phone: 828-329-6010 Fax: 828-765-9655 |
Kaitlyn Hobbs, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 125 Hospital Dr, Spruce Pine, NC 28777 Phone: 828-765-4201 |
Katherine L Mcdonald-coxen, M.S. SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 218 Laurel Creek Ct, Spruce Pine, NC 28777 Phone: 828-765-7312 |
News Archive
History of preeclampsia increases lifetime risk for cardiovascular illness and death
In a study of mothers with a history of preeclampsia, a hypertension complication in pregnancy affecting five percent of all women, researchers at Yale have found that these women have an increased lifetime risk for cardiovascular illness and death.
Positive results from OMS201 Phase 1/2 trial in patients undergoing urologic procedures
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical trial of OMS201, the Company's urological PharmacoSurgery™ product candidate.
Comtex SmarTrend ranks POZEN as second most efficient pharmaceutical company
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.
SENIOR trial: Shorter DAPT combined with Synergy stent superior to BMS in elderly patients
Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk. However, results from the SENIOR trial found that compared with BMS, shorter DAPT combined with the Synergy bioabsorbable polymer DES leads to less adverse events without increasing bleeding risk.
› Verified 4 days ago
Physical Therapists
Optometrists
Occupational Therapists
Speech-Language Pathologists
Chiropractors
Podiatrists